Washington, D.C. 20549
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 2003
Commission File Number 0-26670
(Exact name of registrant as specified in its charter)
|
Delaware |
|
51-0366422 |
|
(State or
other jurisdiction of |
|
(I.R.S. Employer |
|
|
|
|
|
20200 Sunburst Street, Chatsworth, CA 91311 |
||
|
(Address of principal executive offices) |
||
|
|
|
|
|
(818) 734-8600 |
||
|
(Registrant’s telephone number, including area code) |
||
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý
The number of shares of Registrant’s Common Stock, $.01 par value, outstanding as of August 29, 2003 was 10,257,741 shares.
NORTH AMERICAN SCIENTIFIC, INC.
Index
2
NORTH AMERICAN SCIENTIFIC, INC.
|
|
|
July 31, |
|
October
31, |
|
||
|
|
|
(Unaudited) |
|
|
|
||
|
|
|
|
|
|
|
||
|
Assets |
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
Current assets |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
2,035,000 |
|
$ |
2,708,000 |
|
|
Marketable securities |
|
31,683,000 |
|
36,144,000 |
|
||
|
Accounts receivable |
|
2,024,000 |
|
2,416,000 |
|
||
|
Inventories |
|
723,000 |
|
596,000 |
|
||
|
Income taxes receivable |
|
— |
|
1,006,000 |
|
||
|
Prepaid expenses and other current assets |
|
1,460,000 |
|
833,000 |
|
||
|
|
|
|
|
|
|
||
|
Total current assets |
|
37,925,000 |
|
43,703,000 |
|
||
|
|
|
|
|
|
|
||
|
Non-current marketable securities |
|
17,886,000 |
|
17,093,000 |
|
||
|
Equipment and leasehold improvements |
|
2,935,000 |
|
3,264,000 |
|
||
|
Goodwill |
|
3,659,000 |
|
3,659,000 |
|
||
|
Licenses and patents |
|
381,000 |
|
469,000 |
|
||
|
Deferred income taxes |
|
844,000 |
|
844,000 |
|
||
|
Other assets |
|
109,000 |
|
103,000 |
|
||
|
|
|
|
|
|
|
||
|
Total assets |
|
$ |
63,739,000 |
|
$ |
69,135,000 |
|
|
|
|
|
|
|
|
||
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
Current liabilities |
|
|
|
|
|
||
|
Accounts payable |
|
$ |
1,052,000 |
|
$ |
1,109,000 |
|
|
Accrued expenses |
|
3,986,000 |
|
3,125,000 |
|
||
|
|
|
|
|
|
|
||
|
Total current liabilities |
|
5,038,000 |
|
4,234,000 |
|
||
|
|
|
|
|
|
|
||
|
Commitments and contingencies |
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
Stockholders’ equity |
|
|
|
|
|
||
|
Preferred stock, $.01 par value, 2,000,000 shares authorized; no shares issued or outstanding |
|
— |
|
— |
|
||
|
Common stock, $.01 par value, 40,000,000 shares authorized; 10,276,741 and 10,250,136 shares issued and 10,257,741 and 10,250,136 outstanding as of July 31, 2003 and October 31, 2002, respectively |
|
103,000 |
|
103,000 |
|
||
|
Additional paid-in capital |
|
74,147,000 |
|
73,929,000 |
|
||
|
Treasury stock, at cost – 19,000 common shares |
|
(129,000 |
) |
— |
|
||
|
Accumulated deficit |
|
(15,420,000 |
) |
(9,131,000 |
) |
||
|
|
|
|
|
|
|
||
|
Total stockholders’ equity |
|
58,701,000 |
|
64,901,000 |
|
||
|
|
|
|
|
|
|
||
|
Total liabilities and stockholders’ equity |
|
$ |
63,739,000 |
|
$ |
69,135,000 |
|
See condensed notes to the consolidated financial statements.
3
NORTH AMERICAN SCIENTIFIC, INC.
Consolidated Statements of Operations
(Unaudited)
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||
|
|
|
2003 |
|
2002 |
|
2003 |
|
2002 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net sales |
|
$ |
3,011,000 |
|
$ |
5,267,000 |
|
$ |
11,056,000 |
|
$ |
15,160,000 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of goods sold |
|
1,733,000 |
|
1,912,000 |
|
4,988,000 |
|
5,554,000 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Gross profit |
|
1,278,000 |
|
3,355,000 |
|
6,068,000 |
|
9,606,000 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Selling, general and administrative expenses |
|
2,704,000 |
|
1,569,000 |
|
8,149,000 |
|
4,433,000 |
|
||||
|
Research and development |
|
1,661,000 |
|
2,624,000 |
|
5,431,000 |
|
6,993,000 |
|
||||
|
Write-off of licenses and equipment |
|
— |
|
— |
|
— |
|
2,714,000 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Loss from operations |
|
(3,087,000 |
) |
(838,000 |
) |
(7,512,000 |
) |
(4,534,000 |
) |
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest and other income, net |
|
250,000 |
|
488,000 |
|
1,534,000 |
|
1,444,000 |
|
||||
|
|
|
|
|
||||||||||